{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:03:37Z","timestamp":1793898217474,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.lungcan.2025.108854","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:20Z","timestamp":1764028820000},"page":"108854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5782-7912","authenticated-orcid":false,"given":"Marliese","family":"Alexander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malinda","family":"Itchins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Felthun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Nagrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony J.","family":"Mersiades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett G.M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Warburton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Y.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prunella","family":"Blinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Bowyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Clay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2025.108854_b0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108854_b0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8504","article-title":"Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: a secondary analysis from the phase 3 MARIPOSA study","author":"Felip","year":"2024","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108854_b0015","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108854_b0020","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108854_b0025","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108854_b0030","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11523-024-01072-x","article-title":"Impact of Pd-L1 expression on the overall survival of caucasian patients with advanced EGFR-mutant Nsclc treated with frontline osimertinib","volume":"19","author":"Papazyan","year":"2024","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108854_b0035","doi-asserted-by":"crossref","first-page":"9753","DOI":"10.1038\/s41598-022-13102-7","article-title":"PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment na\u00efve advanced EGFR-mutant non-small cell lung cancer patients","volume":"12","author":"Hsu","year":"2022","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108854_b0040","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.21873\/anticanres.15736","article-title":"Prognostic implication of PD-L1 expression on osimertinib treatment for EGFR-mutated non-small cell lung cancer","volume":"42","author":"Shiozawa","year":"2022","journal-title":"Anticancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108854_b0045","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.21037\/tlcr-21-461","article-title":"Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study","volume":"10","author":"Yoshimura","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108854_b0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3892\/mco.2024.2741","article-title":"Comparison of the efficacy of first\u2011\/second\u2011generation EGFR\u2011tyrosine kinase inhibitors and osimertinib for EGFR\u2011mutant lung cancer with negative or low PD\u2011L1 expression","volume":"20","author":"Inomata","year":"2024","journal-title":"Mol. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108854_b0055","doi-asserted-by":"crossref","first-page":"515","DOI":"10.21873\/cdp.10357","article-title":"Comparing the effectiveness of afatinib and osimertinib for patients with PD-L1-positive EGFR-mutant non-small cell carcinoma","volume":"4","author":"Inomata","year":"2024","journal-title":"Cancer Diag. Prog."},{"issue":"17","key":"10.1016\/j.lungcan.2025.108854_b0060","doi-asserted-by":"crossref","first-page":"17788","DOI":"10.1002\/cam4.6405","article-title":"Association of PD\u2010L1 tumor proportion score\u2265 20% with early resistance to osimertinib in patients with EGFR\u2010mutated NSCLC","volume":"12","author":"Hamakawa","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2025.108854_b0065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation\u2013positive non\u2013small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108854_b0070","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jtho.2019.09.009","article-title":"Programmed cell death ligand 1 expression in untreated EGFR mutated advanced NSCLC and response to osimertinib versus comparator in FLAURA","volume":"15","author":"Brown","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108854_b0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2021.03.004","article-title":"Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors","volume":"155","author":"Liu","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108854_b0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejca.2019.10.019","article-title":"Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors","volume":"124","author":"Yang","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108854_b0085","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D'incecco","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"16","key":"10.1016\/j.lungcan.2025.108854_b0090","doi-asserted-by":"crossref","first-page":"14209","DOI":"10.18632\/oncotarget.3694","article-title":"The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs","volume":"6","author":"Tang","year":"2015","journal-title":"Oncotarget"},{"issue":"1\u20132","key":"10.1016\/j.lungcan.2025.108854_b0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbrc.2015.05.030","article-title":"EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-\u03baB","volume":"463","author":"Lin","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lungcan.2025.108854_b0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.lungcan.2017.01.008","article-title":"Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer","volume":"105","author":"Soo","year":"2017","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2025.108854_b0105","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jtho.2018.07.016","article-title":"Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation","volume":"13","author":"Su","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2025.108854_b0110","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1111\/1759-7714.14608","article-title":"Retrospective analysis of independent predictors of progression\u2010free survival in patients with EGFR mutation\u2010positive advanced non\u2010small cell lung cancer receiving first\u2010line osimertinib","volume":"13","author":"Teranishi","year":"2022","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.lungcan.2025.108854_b0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lungcan.2018.11.021","article-title":"High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment na\u00efve advanced EGFR-mutant lung adenocarcinoma patients","volume":"127","author":"Hsu","year":"2019","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108854_b0120","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1080\/0284186X.2020.1807600","article-title":"Impact of programmed death-ligand 1 expression on the patients of stage IV non-small cell lung cancer harboring epidermal growth factor receptor mutation: a systematic review and meta-analysis","volume":"59","author":"Lee","year":"2020","journal-title":"Acta Oncol."},{"key":"10.1016\/j.lungcan.2025.108854_b0125","unstructured":"A.N.Z.C.T. Registry, AUstralasian thoRacic cancers lOngitudinal cohoRt study and biobAnk (AURORA), Last updated: 16\/1\/2025. https:\/\/www.anzctr.org.au\/. 2025)."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108854_b0130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.lungcan.2013.08.011","article-title":"Evaluation of the Simplified Comorbidity score (Colinet) as a prognostic indicator for patients with lung cancer: a cancer registry study","volume":"82","author":"Ball","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108854_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00013","article-title":"Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non-small-cell lung cancer data set","volume":"3","author":"Griffith","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108854_b0140","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2016","journal-title":"JNCI: J. Nat. Cancer Inst."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108854_b0145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108854_b0150","first-page":"1","article-title":"The role of PD-L1 in EGFR-mutant non-small cell lung cancer","volume":"16","author":"Gao","year":"2025","journal-title":"Discov. Oncol."},{"issue":"35","key":"10.1016\/j.lungcan.2025.108854_b0155","doi-asserted-by":"crossref","first-page":"58457","DOI":"10.18632\/oncotarget.17022","article-title":"PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108854_b0160","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108854_b0165","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/fon-2021-0923","article-title":"MARIPOSA: phase 3 study of first-line amivantamab+ lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer","volume":"18","author":"Cho","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2025.108854_b0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2022.10.012","article-title":"PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer","volume":"178","author":"Saw","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"18","key":"10.1016\/j.lungcan.2025.108854_b0175","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108854_b0180","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cllc.2020.11.004","article-title":"Osimertinib maintenance after definitive chemoradiation in patients with unresectable EGFR mutation positive stage III non\u2013small-cell lung cancer: LAURA trial in progress","volume":"22","author":"Lu","year":"2021","journal-title":"Clin. Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T17:22:10Z","timestamp":1769448130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225007469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"alternative-id":["S0169500225007469"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108854","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108854"}}